Alkermes wins FDA fast track; Aslan raises $22M for R&D work; The genetics of negative thinking

@FierceBiotech: Popular yesterday: 10 top drugs in biopharma's late-stage pipeline. Feature | Follow @FierceBiotech

@JohnCFierce: Few months after $60M C series and Forest deal, Trevena files for $86M IPO. SEC filing | Press release | Follow @JohnCFierce

@DamianFierce: MacroGenics has up-sized its IPO, now seeking $80M amid biotech blitz. ICYMI yesterday | Follow @DamianFierce

@EmilyMFierce: 3-D printing builds bacterial metropolises. More via ScienceNews | Follow @EmilyMFierce

> The FDA is putting Alkermes' ($ALKS) ALKS 5461 on the fast track. The biotech company is developing the drug for major depression. Release

> Singapore-based Aslan Pharmaceuticals has raised $22 million in a Series B. The biotech's model is to in-license preclinical therapies, take them through Phase II and then partner them out. Story

Medical Device News

@FierceMedDev: Medtronic jumps into hemodialysis business through India partnership. ICYMI yesterday | Follow @FierceMedDev

@MarkHFierce: The head of Roche molecular diagnostics spoke to FierceDiagnostics recently about two key future products. More | Follow @MarkHFierce

@MichaelGFierce: Check out this week's FierceDrugDelivery newsletter! RNAi roundup & stem cell drug delivery action. Report | Follow @MichaelGFierce

> Are medical device companies invited to the biotech IPO party? Editor's corner

> Boston Scientific kicks off drug-eluting stent trial as sales wane. Story

> Quest warns reimbursement pressures, test volume declines will dampen Q3. More

> FDA panel casts doubt on CardioMEMS' heart failure diagnostic. Article

Pharma News

@FiercePharma: Top 10 Drugmakers in Emerging Markets--our latest special report. Feature | Follow @FiercePharma

@CarlyHFierce: Teva: Copying GlaxoSmithKline's Advair too tough for success before 2018. ICYMI yesterday | Follow @CarlyHFierce

> Which new drugs promise to shake up markets the most? Report

> Express Scripts stops covering key Big Pharma drugs on cost-effectiveness grounds. Story

> Teva plots 5,000 more job cuts in $2B savings drive. News

Pharma Manufacturing News

@EricPFierce: Will McKesson and AmerisourceBergen now face off in Europe? Article | Follow @EricPFierce

> Catalent moves on Brazil VMS, softgel market. News

> Vetter putting $100M into its production network. Report

> Teva looks for big savings from procurement, manufacturing. Story

> Feds fight drug imports Maine now allows. More

> BioCentury finds FDA has $270M in GDUFA, PDUFA fees in hand. Item

Vaccines News

> WHO prequalification moves China into global vaccine arena. Item

> Novartis opening vaccine R&D lab in North Carolina. Report

> Takeda's norovirus vaccine misses endpoint in early-phase trial. Story

> GSK targets 2015 launch for malaria vaccine. Article

> HIV trial follow-up quashes fears of infection risk. More

And Finally… Drawn to the dark side? You may be genetically predisposed. Release

Suggested Articles

It’s been a good year for Intellia: One of its founders, Jennifer Doudna, Ph.D., nabbed the Nobel Prize in Chemistry for her CRISPR research.

After stints at Eli Lilly, Boehringer Ingelheim and Bristol Myers Squibb, Sid Kerkar, M.D., is hopping over to a small biotech.

Two long noncoding RNAs called TROLL-2 and TROLL-3 influence protein signaling to drive the progression of breast cancer, a new study revealed.